Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Brooks, Sarah A
- An Unusual Case of Hodgkin's PTLD more than 10 Years after Kidney Transplantation in a Child
Abstract Views :264 |
PDF Views:0
Authors
Hawazen Alsaedi
1,
Rebecca Cafiero
1,
Sarah A Brooks
2,
Sally Self
2,
Michelle P Hudspeth
1,
Katherine Twombley
3
Affiliations
1 Department of Pediatrics, Division of Oncology, Medical University of South Carolina, SC, US
2 Department of Pathology, Medical University of South Carolina, SC, US
3 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
1 Department of Pediatrics, Division of Oncology, Medical University of South Carolina, SC, US
2 Department of Pathology, Medical University of South Carolina, SC, US
3 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 50-54Abstract
PTLD (post-transplant lymphoproliferative disorder) is a serious complication of immunosuppression seen in patients after solid organ and bone marrow transplantation. The overall incidence of PTLD in children as reported by the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) is 1.2%, and the incidence of Hodgkin lymphoma (HL) is even rarer. The Epstein-Barr virus plays an important role in the pathogenesis of post-transplant lymphomas because of its ability to transform infected cells. Differentiating PTLD from malignant lymphomas, especially HL can be challenging, but it is vitally necessary as the treatments differ greatly.Keywords
Kidney, Post-transplant Lymphoproliferative Disorder, Transplant, Hodgkin
References
- Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE, 2001. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065-8.
- Twombley K, Pokala H, Ardura MI, et al., 2012. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 16:E201-9.
- Schober T, Framke T, Kreipe H, et al., 2013. Character-istics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240-6.
- Schwartz CL, Constine LS, Villaluna D, et al., 2009. A riskadapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-9.
- Birk PE, Stannard KM, Konrad HB, et al., 2004. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 8:29-38.
- Vegso G, Hajdu M, Sebestyen A, 2011. Lymphoproliferative disorders after solid organ transplantation—classifi-cation, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 17:443-54.
- Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS, 2004. Hodgkin’s lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 8:87- 90.
- Rohr JC, Wagner HJ, Lauten M, et al., 2008. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkinlike post-transplant lymphoproliferative disease. Pediatr Transplant 12:426-31.
- Goyal RK, McEvoy L, Wilson DB, 1996. Hodgkin disease after renal transplantation in childhood. J Pediatr Hematol Oncol 18:392-5.
- Bierman PJ, Vose JM, Langnas AN, et al., 1996. Hodgkin’s disease following solid organ transplantation. Ann Oncol 7:265- 70.
- Nalesnik MA, Randhawa P, Demetris AJ, Casavilla A, Fung JJ, Locker J, 1993. Lymphoma resembling Hodgkin disease after post-transplant lymphoproliferative disorder in a liver transplant recipient. Cancer 72:2568-73.
- Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD, 2005. Maintenance immunosuppression with target-ofrapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883-9.
- Campistol JM, Eris J, Oberbauer R, et al., 2006. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17:581-9.
- Alberu J, Pascoe MD, Campistol JM, et al., 2011. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24- month results from the CONVERT trial. Transplantation 92:303- 10.
- Degi A, Kerti A, Kis E, et al., 2012. Cardiovascular risk assessment in children following kidney transplantation. Pediatr Transplant 16:564-76.
- Mitsnefes MM, 2012. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578-85.